Trial Outcomes & Findings for A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis (NCT NCT00267969)

Last Updated: 2013-06-17

Results Overview

The number of participants achieving at least 75% improvement from baseline in Psoriasis Area and Severity Index (PASI) (0 \[best\] - 72 \[worst\]) at Week 12. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

766 participants

Primary outcome timeframe

Week 12

Results posted on

2013-06-17

Participant Flow

In this study, 766 patients were randomized in North America and Europe to receive either placebo or ustekinumab (CNTO 1275).

Participant milestones

Participant milestones
Measure	Placebo (CP) Controlled period (Week 0-12) - Placebo group	Ustekinumab 45 mg (CP) Controlled period (Week 0-12) - Ustekinumab 45 mg group	Ustekinumab 90 mg (CP) Controlled period (Week 0-12) - Ustekinumab 90 mg group	Placebo -> Ustekinumab 45 mg (After CP) After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 45 mg every 12 weeks (q12wk) or every 8 weeks (q8wk) from Week 12 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 45 q12w.	Placebo -> Ustekinumab 90 mg (After CP) After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 12 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 90 q12w.	Ustekinumab 45 mg (After CP) After Controlled period (Week 12-264) - patients receiving ustekinumab 45 mg at Weeks 0 and 4 -\> receiving ustekinumab 45 mg q12wk or q8wk from Week 16 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 45 q12w.	Ustekinumab 90 mg (After CP) After Controlled period (Week 12-264) - patients receiving ustekinumab 90 mg at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 16 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 90 q12w.
Controlled Period STARTED	255	255	256	0	0	0	0
Controlled Period COMPLETED	243	254	245	0	0	0	0
Controlled Period NOT COMPLETED	12	1	11	0	0	0	0
After Controlled Period STARTED	0	0	0	123	120	254	245
After Controlled Period COMPLETED	0	0	0	87	85	172	173
After Controlled Period NOT COMPLETED	0	0	0	36	35	82	72

Reasons for withdrawal

Reasons for withdrawal
Measure	Placebo (CP) Controlled period (Week 0-12) - Placebo group	Ustekinumab 45 mg (CP) Controlled period (Week 0-12) - Ustekinumab 45 mg group	Ustekinumab 90 mg (CP) Controlled period (Week 0-12) - Ustekinumab 90 mg group	Placebo -> Ustekinumab 45 mg (After CP) After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 45 mg every 12 weeks (q12wk) or every 8 weeks (q8wk) from Week 12 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 45 q12w.	Placebo -> Ustekinumab 90 mg (After CP) After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 12 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 90 q12w.	Ustekinumab 45 mg (After CP) After Controlled period (Week 12-264) - patients receiving ustekinumab 45 mg at Weeks 0 and 4 -\> receiving ustekinumab 45 mg q12wk or q8wk from Week 16 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 45 q12w.	Ustekinumab 90 mg (After CP) After Controlled period (Week 12-264) - patients receiving ustekinumab 90 mg at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 16 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 90 q12w.
Controlled Period Adverse Event	6	0	2	0	0	0	0
Controlled Period Lack of Efficacy	3	0	1	0	0	0	0
Controlled Period Lost to Follow-up	1	0	1	0	0	0	0
Controlled Period Randomized but not treated	0	0	1	0	0	0	0
Controlled Period Other	2	1	6	0	0	0	0
After Controlled Period Adverse Event	0	0	0	7	8	23	21
After Controlled Period Death	0	0	0	1	2	0	1
After Controlled Period Lack of Efficacy	0	0	0	10	6	28	15
After Controlled Period Lost to Follow-up	0	0	0	5	8	9	10
After Controlled Period Other	0	0	0	13	11	22	25

Baseline Characteristics

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=255 Participants Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.	Ustekinumab 45 mg n=255 Participants Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.	Ustekinumab 90 mg n=256 Participants Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.	Total n=766 Participants Total of all reporting groups
Age Continuous	44.8 Years STANDARD_DEVIATION 11.32 • n=5 Participants	44.8 Years STANDARD_DEVIATION 12.48 • n=7 Participants	46.2 Years STANDARD_DEVIATION 11.27 • n=5 Participants	45.3 Years STANDARD_DEVIATION 11.71 • n=4 Participants
Sex: Female, Male Female	72 Participants n=5 Participants	80 Participants n=7 Participants	83 Participants n=5 Participants	235 Participants n=4 Participants
Sex: Female, Male Male	183 Participants n=5 Participants	175 Participants n=7 Participants	173 Participants n=5 Participants	531 Participants n=4 Participants

PRIMARY outcome

Timeframe: Week 12

Population: Intent to treat. All patients randomized were included in the analysis according to the assigned treatment groups. Patient is considered a non- responder if the patient has used any pre-specified prohibited medications or discontinued due to lack of efficacy, or an AE of worsening of psoriasis, or had missing data at Week 12.

Outcome measures

Outcome measures
Measure	Placebo n=255 Participants Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.	Ustekinumab 45 mg n=255 Participants Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.	Ustekinumab 90 mg n=256 Participants Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.	Group 4: Ustekinumab 90 mg Every 12 Weeks Patients received ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40.	Group 5: Withdrawal Combined Group Groups 1 and 3 (Withdrawal Combined)	Group 6: Combined Ustekinumab Every 12 Weeks Groups 2 and 4 (Combined Ustekinumab every 12 weeks)
Psoriasis Area-and-severity Index (PASI) 75% Improvement From Baseline at Week 12.	8 Participants	171 Participants	170 Participants	—	—	—

SECONDARY outcome

Timeframe: Week 12

Population: Intent to treat. All patients were included in the analysis according to the assigned treatment groups. Patient is considered a non- responder if the patient has used any pre-specified prohibited medications or discontinued due to lack of efficacy, or an AE of worsening of psoriasis, or had missing data at Week 12.

The PGA is used to determine the participant's psoriasis lesions overall at a given time point. Overall lesions will be graded as : (0) = cleared, (1) = minimal, (2) = mild, (3) = moderate, (4) = marked, and (5) = severe for induration, erythema, and scaling. The sum of the 3 scales will be divided by 3 to obtain a final PGA score ranging from 0 \[best\] to 5 \[worst\].

Outcome measures

Outcome measures
Measure	Placebo n=255 Participants Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.	Ustekinumab 45 mg n=255 Participants Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.	Ustekinumab 90 mg n=256 Participants Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.	Group 4: Ustekinumab 90 mg Every 12 Weeks Patients received ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40.	Group 5: Withdrawal Combined Group Groups 1 and 3 (Withdrawal Combined)	Group 6: Combined Ustekinumab Every 12 Weeks Groups 2 and 4 (Combined Ustekinumab every 12 weeks)
Number of Participants Who Achieved a Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12	10 participants	151 participants	156 participants	—	—	—

SECONDARY outcome

Timeframe: Baseline (Week 0), Week 12

Population: Patients were included in the analysis according to the assigned treatment groups. Zero change is imputed if the patient has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.

Change from baseline in Dermatology Life Quality Index (DLQI) from baseline at Week 12. This DLQI is a 10-item questionnaire, that in addition to evaluating overall quality of life, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Scores range from 0 (no impairment in quality of life) to 30 (most impairment in quality of life).

Outcome measures

Outcome measures
Measure	Placebo n=252 Participants Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.	Ustekinumab 45 mg n=254 Participants Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.	Ustekinumab 90 mg n=249 Participants Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.	Group 4: Ustekinumab 90 mg Every 12 Weeks Patients received ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40.	Group 5: Withdrawal Combined Group Groups 1 and 3 (Withdrawal Combined)	Group 6: Combined Ustekinumab Every 12 Weeks Groups 2 and 4 (Combined Ustekinumab every 12 weeks)
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 12	0.0 Scores on a scale Interval -3.0 to 3.0	-6.0 Scores on a scale Interval -12.0 to -3.0	-7.0 Scores on a scale Interval -12.0 to -4.0	—	—	—

SECONDARY outcome

Timeframe: Week 52

Population: Patients were included in the analysis according to the assigned treatment groups. Patient is considered a non- responder if the patient has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.

The number of participants achieving at least 75% improvement from baseline in Psoriasis Area and Severity Index (PASI) (0 \[best\] - 72 \[worst\]) at Week 52 in participants randomly assigned to a treatment group at Week 40. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.

Outcome measures

Outcome measures
Measure	Placebo n=73 Participants Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.	Ustekinumab 45 mg n=77 Participants Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.	Ustekinumab 90 mg n=86 Participants Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.	Group 4: Ustekinumab 90 mg Every 12 Weeks n=85 Participants Patients received ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40.	Group 5: Withdrawal Combined Group n=159 Participants Groups 1 and 3 (Withdrawal Combined)	Group 6: Combined Ustekinumab Every 12 Weeks n=162 Participants Groups 2 and 4 (Combined Ustekinumab every 12 weeks)
Psoriasis Area and Severity Index (PASI) 75 Responders at Week 52	47 participants	67 participants	53 participants	77 participants	100 participants	144 participants

Adverse Events

Placebo (CP)

Serious events: 2 serious events

Other events: 81 other events

Deaths: 0 deaths

Ustekinumab 45 mg (CP)

Serious events: 2 serious events

Other events: 102 other events

Deaths: 0 deaths

Ustekinumab 90 mg (CP)

Serious events: 4 serious events

Other events: 84 other events

Deaths: 0 deaths

Placebo -> Ustekinumab 45 mg (After CP)

Serious events: 20 serious events

Other events: 110 other events

Deaths: 0 deaths

Placebo -> Ustekinumab 90 mg (After CP)

Serious events: 18 serious events

Other events: 102 other events

Deaths: 0 deaths

Ustekinumab 45 mg (After CP)

Serious events: 38 serious events

Other events: 207 other events

Deaths: 0 deaths

Ustekinumab 90 mg (After CP)

Serious events: 33 serious events

Other events: 207 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Placebo (CP) n=255 participants at risk Controlled period (Week 0-12) - Placebo group	Ustekinumab 45 mg (CP) n=255 participants at risk Controlled period (Week 0-12) - Ustekinumab 45 mg group	Ustekinumab 90 mg (CP) n=255 participants at risk Controlled period (Week 0-12) - Ustekinumab 90 mg group	Placebo -> Ustekinumab 45 mg (After CP) n=123 participants at risk After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 45 mg every 12 weeks (q12wk) or every 8 weeks (q8wk) from Week 12 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 45 q12w.	Placebo -> Ustekinumab 90 mg (After CP) n=120 participants at risk After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 12 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 90 q12w.	Ustekinumab 45 mg (After CP) n=255 participants at risk After Controlled period (Week 12-264) - patients receiving ustekinumab 45 mg at Weeks 0 and 4 -\> receiving ustekinumab 45 mg q12wk or q8wk from Week 16 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 45 q12w.	Ustekinumab 90 mg (After CP) n=251 participants at risk After Controlled period (Week 12-264) - patients receiving ustekinumab 90 mg at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 16 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 90 q12w.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thyroid cancer	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Blood and lymphatic system disorders Anaemia	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Cardiac disorders Acute myocardial infarction	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Cardiac disorders Angina pectoris	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Cardiac disorders Angina unstable	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Cardiac disorders Atrial fibrillation	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.6% 2/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Cardiac disorders Atrial flutter	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Cardiac disorders Cardiac failure congestive	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Cardiac disorders Cardiomegaly	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Cardiac disorders Coronary artery disease	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.5% 3/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.2% 3/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Cardiac disorders Coronary artery occlusion	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Cardiac disorders Myocardial infarction	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.7% 2/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Cardiac disorders Ventricular tachycardia	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Congenital, familial and genetic disorders Polydactyly	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Ear and labyrinth disorders Deafness neurosensory	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Abdominal pain	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Ascites	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Colitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Diverticular perforation	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Gastritis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Intestinal perforation	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Pancreatitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Peritonitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
General disorders Chest discomfort	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
General disorders Chest pain	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.80% 2/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
General disorders Drug withdrawal syndrome	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Hepatobiliary disorders Autoimmune hepatitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Hepatobiliary disorders Cholecystitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Hepatobiliary disorders Cholelithiasis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Hepatobiliary disorders Chronic hepatic failure	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Hepatobiliary disorders Liver disorder	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Appendicitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Appendicitis perforated	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.6% 2/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Asymptomatic HIV infection	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Bronchitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Cellulitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Clostridium difficile colitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Diarrhoea infectious	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Diverticulitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Empyema	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Endocarditis bacterial	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Gastroenteritis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Herpes zoster disseminated	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Meningitis aseptic	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Necrotising fasciitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Osteomyelitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Pneumonia	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Postoperative wound infection	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Pyelonephritis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Viral infection	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Alcohol poisoning	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Anaesthetic complication	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Cervical vertebral fracture	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Chest injury	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Femur fracture	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Foreign body	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Gun shot wound	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Humerus fracture	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Lower limb fracture	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Overdose	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Rib fracture	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Uterine perforation	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Investigations Blood pressure increased	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Metabolism and nutrition disorders Dehydration	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lymphoma	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma in situ	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma metastatic	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Transitional cell carcinoma	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Nervous system disorders Cerebrovascular accident	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Nervous system disorders Chorea	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Nervous system disorders Dizziness	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Nervous system disorders Headache	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Nervous system disorders Presyncope	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Nervous system disorders Transient ischaemic attack	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Pregnancy, puerperium and perinatal conditions Abortion spontaneous	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Psychiatric disorders Alcohol abuse	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Psychiatric disorders Completed suicide	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Psychiatric disorders Delirium	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Psychiatric disorders Depression	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Psychiatric disorders Psychotic disorder	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Renal and urinary disorders Nephrolithiasis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Renal and urinary disorders Renal colic	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Renal and urinary disorders Renal failure	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Renal and urinary disorders Renal infarct	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Reproductive system and breast disorders Endometrial hyperplasia	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Reproductive system and breast disorders Menorrhagia	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Reproductive system and breast disorders Ovarian cyst	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Respiratory, thoracic and mediastinal disorders Asthma	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.40% 1/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Respiratory, thoracic and mediastinal disorders Sleep apnoea syndrome	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Skin and subcutaneous tissue disorders Dermatitis allergic	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.83% 1/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Skin and subcutaneous tissue disorders Drug eruption	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Skin and subcutaneous tissue disorders Psoriasis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Vascular disorders Hypertension	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Vascular disorders Hypotension	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.

Other adverse events

Other adverse events
Measure	Placebo (CP) n=255 participants at risk Controlled period (Week 0-12) - Placebo group	Ustekinumab 45 mg (CP) n=255 participants at risk Controlled period (Week 0-12) - Ustekinumab 45 mg group	Ustekinumab 90 mg (CP) n=255 participants at risk Controlled period (Week 0-12) - Ustekinumab 90 mg group	Placebo -> Ustekinumab 45 mg (After CP) n=123 participants at risk After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 45 mg every 12 weeks (q12wk) or every 8 weeks (q8wk) from Week 12 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 45 q12w.	Placebo -> Ustekinumab 90 mg (After CP) n=120 participants at risk After Controlled period (Week 12-264) - patients receiving Placebo at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 12 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 90 q12w.	Ustekinumab 45 mg (After CP) n=255 participants at risk After Controlled period (Week 12-264) - patients receiving ustekinumab 45 mg at Weeks 0 and 4 -\> receiving ustekinumab 45 mg q12wk or q8wk from Week 16 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 45 q12w.	Ustekinumab 90 mg (After CP) n=251 participants at risk After Controlled period (Week 12-264) - patients receiving ustekinumab 90 mg at Weeks 0 and 4 -\> receiving ustekinumab 90 mg q12wk or q8wk from Week 16 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 90 q12w.
Gastrointestinal disorders Abdominal pain	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.5% 3/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.1% 13/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	3.2% 8/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Diarrhoea	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.6% 4/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.1% 5/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	7.5% 9/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	7.1% 18/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	7.2% 18/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Dyspepsia	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.6% 4/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	3.3% 4/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.7% 2/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.1% 13/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.6% 4/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Gastrointestinal disorders Nausea	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.6% 4/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.7% 7/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.5% 3/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.7% 12/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.0% 10/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
General disorders Fatigue	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.0% 5/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.4% 6/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	7.3% 9/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.2% 5/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	3.1% 8/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.0% 5/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Bronchitis	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	8.9% 11/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	13.3% 16/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	9.8% 25/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	11.6% 29/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Cellulitis	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.0% 6/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.7% 7/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.0% 5/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Gastroenteritis	2.0% 5/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.4% 6/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	8.9% 11/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	9.2% 11/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	9.0% 23/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	10.0% 25/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Gastroenteritis viral	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.0% 6/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.7% 12/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.8% 7/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Influenza	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	13.0% 16/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	12.5% 15/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	11.0% 28/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	10.8% 27/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Nasopharyngitis	8.6% 22/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	10.2% 26/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	8.2% 21/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	38.2% 47/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	30.0% 36/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	27.5% 70/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	29.9% 75/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Pharyngitis	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	7.3% 9/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.0% 6/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.3% 11/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.8% 12/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Sinusitis	2.4% 6/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.4% 6/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.6% 4/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	12.2% 15/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	11.7% 14/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	14.5% 37/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	12.4% 31/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Tooth abscess	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.1% 5/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.8% 7/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	6.3% 16/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.2% 13/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Upper respiratory tract infection	6.3% 16/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	7.1% 18/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	6.3% 16/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	35.0% 43/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	28.3% 34/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	32.2% 82/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	30.7% 77/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Urinary tract infection	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.4% 3/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.0% 6/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.5% 14/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	3.6% 9/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Infections and infestations Viral upper respiratory tract infection	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.6% 4/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.1% 5/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	8.3% 10/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	7.5% 19/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.6% 14/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Laceration	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.7% 7/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	3.3% 4/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.5% 14/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	6.0% 15/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Muscle strain	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	8.9% 11/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	7.5% 9/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	8.6% 22/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	6.8% 17/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.4% 3/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	10.8% 13/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.5% 14/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.4% 11/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Metabolism and nutrition disorders Hypercholesterolaemia	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	8.1% 10/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.0% 6/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	3.9% 10/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.8% 7/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Musculoskeletal and connective tissue disorders Arthralgia	2.7% 7/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.7% 7/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.4% 6/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	16.3% 20/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	10.8% 13/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	12.2% 31/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	13.1% 33/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Musculoskeletal and connective tissue disorders Arthritis	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	3.3% 4/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.8% 7/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.7% 7/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	3.2% 8/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Musculoskeletal and connective tissue disorders Back pain	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.4% 6/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.7% 7/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	10.6% 13/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	15.0% 18/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	9.0% 23/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	10.8% 27/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.7% 7/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	8.3% 10/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.7% 7/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	6.0% 15/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Musculoskeletal and connective tissue disorders Psoriatic arthropathy	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.6% 4/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	7.3% 9/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.7% 2/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	6.3% 16/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.8% 7/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Nervous system disorders Carpal tunnel syndrome	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.0% 6/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.0% 5/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.80% 2/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Nervous system disorders Headache	2.4% 6/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.5% 14/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.1% 13/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	12.2% 15/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.8% 7/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	9.4% 24/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	6.8% 17/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Psychiatric disorders Anxiety	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	3.3% 4/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.0% 6/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	6.3% 16/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.8% 7/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Psychiatric disorders Depression	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.0% 5/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.7% 7/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.0% 6/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	3.1% 8/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.8% 12/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Psychiatric disorders Insomnia	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.7% 7/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.8% 7/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.7% 12/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.6% 14/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Renal and urinary disorders Nephrolithiasis	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.81% 1/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.0% 6/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.7% 7/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.8% 7/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Respiratory, thoracic and mediastinal disorders Cough	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	10.6% 13/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.8% 7/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.1% 13/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	7.2% 18/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.6% 4/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	8.1% 10/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	6.7% 8/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.2% 13/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Skin and subcutaneous tissue disorders Dermatitis contact	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.78% 2/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	10.6% 13/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.2% 5/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.3% 11/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	4.4% 11/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Skin and subcutaneous tissue disorders Night sweats	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.39% 1/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.7% 7/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.7% 2/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.4% 6/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.0% 5/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	0.00% 0/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.7% 7/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	5.0% 6/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.7% 7/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.8% 7/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.
Vascular disorders Hypertension	1.6% 4/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	2.0% 5/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	1.2% 3/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	11.4% 14/123 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	14.2% 17/120 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	8.2% 21/255 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.	12.0% 30/251 • 264 weeks In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.

Additional Information

Dir. Clinical Research

Centocor Research & Development, Inc.

Phone: 1-800-457-6399

Results disclosure agreements

Principal investigator is a sponsor employee Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
Publication restrictions are in place

Restriction type: OTHER